Atomwise
Approach
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve.
Atomwise is addressing
CEO:
Abraham Heifets
Founders:
Dr. Izhar Wallach
Abraham Heifets
First investment:
February 2018